Defense Stocks News; DHS Recent Designations; Wave Dispersion Technologies, Honeywell (NYSE: HON), L-3 Communications (NYSE: LLL) Support Anti-terrorism by Fostering Effective Technologies
SUMMIT, N.J. - April 18, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Investorideas.com , a leader in sector stock research including defense and security stocks reports on recent DHS designations for Support Anti-terrorism by Fostering Effective Technologies Act of 2002, or "SAFETY Act", including private company, Wave Dispersion Technologies, and defense stocks Honeywell (NYSE: HON) and L-3 Communications (NYSE: LLL).
The SAFETY Act provides important legal liability protections for providers of Qualified Anti-Terrorism Technologies - whether they are products or services. The goal of the SAFETY Act is to encourage the development and deployment of new and innovative anti-terrorism products and services by providing liability protections. https://www.safetyact.gov/
The following technologies have been granted "Designation" pursuant to 6 U.S.C. § 441-444 (the Support Anti-terrorism by Fostering Effective Technologies Act of 2002, or "SAFETY Act") and 6 C.F.R. Part 25 (Regulations to Support Anti-terrorism by Fostering Effective Technologies):
Wave Dispersion Technologies, Inc. April 8, 2011 - Wave Dispersion Technologies, Inc., a New Jersey corporation provides WhisprWave® Small Craft Intrusion Barrier™ (the "Technology”), a modular, rapidly deployable floating security barrier system designed to enhance maritime security by deterring, delaying, or impeding small boats traveling at high speed from approaching protected targets. Anchoring of the Technology is customized for each installation and involves use of a commercially available marine-grade anchoring system, based on need. This Designation will expire on March 31, 2016.
Honeywell International Corporation March 16, 2011 - Honeywell International Corporation provides Enterprise Building Integrator. The Technology is a common software control architecture used to control a building or facility's security, life safety, and/or building maintenance (heating, cooling, ventilation, etc.) functions. The Technology also includes design, installation, integration, maintenance support, and customer training, and documentation services provided by Honeywell. The Designation for this Technology does not apply to or provide coverage for Acts of Terrorism that utilize chemical, biological, radiological, or nuclear (CBRN) agents or materials. This Designation will expire on March 31, 2016.
The Port Authority of New York and New Jersey February 28, 2011 - The Port Authority of New York and New Jersey provides the Protective Sleeve for Suspension Bridge Suspender Rope Damage Mitigation. The Technology is a sleeve made of steel and cementitious material. It is designed to increase resistance of bridge suspender ropes to various threats. This Designation will expire on March 31, 2016.
L-3 Communications Security and Detection Systems, Inc. and L-3 Communications Corporation February 23, 2011 - L-3 Communications Security and Detection Systems, Inc. and L-3 Communications Corporation provide the ProvisionTM SC-100 (also known as the Scout 100) and ProVisionTM 360 (also known as the SafeScoutTM 360). The Technology is a line of security portals that use millimeter-wave scanning technology to produce three-dimensional images of subjects to detect threat objects. The Technology also includes training, installation, maintenance services, manuals, and technical documents. This renewed Designation will expire on March 31, 2016.
Company Snapshot: Wave Dispersion Technologies, Inc
http://www.whisprwave.com
Wave Dispersion Technologies, Inc. reports the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT). Wave Dispersion Technologies, the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation.
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation,” said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology,” said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Visit the showcase page on Investorideas.com:
http://www.investorideas.com/Companies/WDT/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer/ disclosure our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: WDT has paid $500 for news release dissemination
www.InvestorIdeas.com/About/Disclaimer.asp
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Monday, April 18, 2011
Biotech Stock Trading Alert; Aethlon Medical (OTCBB: AEMD) Trading up 12% in Morning Trading
PointRoberts
, WA - April 18, 2011 - www.Investorideas.com, a leader in sector stock research including biotech stocks, releases a biotech trading alert for Aethlon Medical (OTCBB:AEMD), a company with technology devices to address infectious disease and cancer. The stock is trading up at $ 0.14, up 0.02 (12.00%) up in early morning trading in volume of over 600,000 shares.
Company Snapshot
About Aethlon Medical (OTCBB: AEMD)
Visit the showcase profile at Investorideas.com
http://www.investorideas.com/CO/AEMD/
Recent News: Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
http://www.investorideas.com/CO/AEMD/news/2011/04151.asp
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the UnitedStates and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All showcase company info is obtained from public filings, news, or directly from management. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com
Point
Company SnapshotAbout Aethlon Medical (OTCBB: AEMD)
Visit the showcase profile at Investorideas.com
http://www.investorideas.com/CO/AEMD/
Recent News: Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
http://www.investorideas.com/CO/AEMD/news/2011/04151.asp
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All showcase company info is obtained from public filings, news, or directly from management. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
SAN DIEGO - April 15, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released an interview with Aethlon CEO Jim Joyce regarding broad spectrum treatment strategies to address HIV, Hepatitis C and other infectious disease conditions. The interview can be accessed online at:
http://www.investorideas.com/CO/AEMD/news/2011/04141.asp
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO - April 15, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released an interview with Aethlon CEO Jim Joyce regarding broad spectrum treatment strategies to address HIV, Hepatitis C and other infectious disease conditions. The interview can be accessed online at:
http://www.investorideas.com/CO/AEMD/news/2011/04141.asp
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Pharma News; BioSante Pharmaceuticals (NASDAQ : BPAX) Announces Pancreatic and Prostate Cancer Vaccine License
LINCOLNSHIRE, Ill. - April 18, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).
BioSante will receive milestone and royalty payments after commercialization of combination cancer vaccines using BioSante's cancer vaccine technology. Aduro also has an option to additional BioSante Cancer Vaccine indications, all for use in combination with Aduro's proprietary vaccine platform.
"We hope that this license agreement will be the first of many that can result in bringing improved cancer treatments to patients and increased value to our stockholders," said Stephen M. Simes, president and CEO of BioSante. "In addition to BioSante's Pancreas and Prostate cancer vaccines, our cancer vaccine portfolio extends into breast, colorectal, leukemia, melanoma and multiple myeloma vaccines," Simes continued.
Aduro plans to initiate a Phase II trial in the fourth quarter of 2011 with approximately 90 late-stage pancreatic cancer patients, using a novel sequential vaccine regimen of BioSante's Pancreas Cancer Vaccine and CRS-207.
CRS-207 is Aduro's lead Lm-based therapeutic and has been engineered to express the tumor-associated antigen, mesothelin. CRS-207 was evaluated in a Phase I trial in 17 end-stage patients with cancers known to express mesothelin: mesothelioma, non-small-cell lung, ovarian and pancreatic. Analysis after the completion of the trial revealed a mesothelin-specific T cell response in multiple patients and despite an expected survival of three-five months for all subjects, six out of 17 subjects lived 15 months or longer.
BioSante cancer vaccines are based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine. BioSante has a portfolio of cancer vaccines, including Pancreas Cancer Vaccine and Prostate Cancer Vaccine. The Pancreas Cancer Vaccine has been evaluated in more than 120 patients and shown to be well tolerated and able to induce mesothelin-specific T cell responses.
Sequential administration of BioSante Pancreas Cancer Vaccine followed by CRS-207 was first shown by Aduro to be synergistic in mouse models, demonstrating enhanced tumor-specific T cell and anti-tumor responses. Because BioSante Pancreas Cancer Vaccine and CRS-207 target the tumor-associated antigen mesothelin, the sequential administration is a heterologous prime-boost regimen. Lm is known to be especially effective in this regimen.
Based on the synergy in preclinical animal models, Drs. Elizabeth Jaffee and Dung Le of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins included three pancreatic cancer patients, in the CRS-207 Phase 1 clinical trial who had previously received the BioSante Pancreas Cancer Vaccine, as part of separate clinical trials. All three late-stage patients who received sequential therapy lived 15 months or longer.
Drs. Jaffee and Le have been instrumental in collaborating with Aduro to design the Phase II trial, which is expected to initiate in the fourth quarter of 2011 and enroll a total of 90 late-stage pancreatic cancer patients. In addition, Dr. Jaffee is one of the original inventors of the BioSante Cancer Vaccines and has many years of experience developing the vaccines.
"The synergy from the sequential administration of BioSante's Pancreas Cancer Vaccine and CRS-207 has the potential to significantly extend and improve the lives of a patient population where progress has historically been measured by extra weeks of survival," said Stephen Isaacs, chairman and chief executive officer of Aduro BioTech. "This partnership may very well represent the future of immunotherapy in which combination therapy becomes the standard."
About Aduro BioTech
Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years and has been validated by 20 major publications and more than $20 million in federal and private grant and contract funding. The company's lead therapeutic, CRS-207, is in clinical development for the treatment of mesothelin-expressing tumors, including pancreatic and non-small-cell lung cancer, and has completed Phase 1.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
LINCOLNSHIRE, Ill. - April 18, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).
BioSante will receive milestone and royalty payments after commercialization of combination cancer vaccines using BioSante's cancer vaccine technology. Aduro also has an option to additional BioSante Cancer Vaccine indications, all for use in combination with Aduro's proprietary vaccine platform.
"We hope that this license agreement will be the first of many that can result in bringing improved cancer treatments to patients and increased value to our stockholders," said Stephen M. Simes, president and CEO of BioSante. "In addition to BioSante's Pancreas and Prostate cancer vaccines, our cancer vaccine portfolio extends into breast, colorectal, leukemia, melanoma and multiple myeloma vaccines," Simes continued.
Aduro plans to initiate a Phase II trial in the fourth quarter of 2011 with approximately 90 late-stage pancreatic cancer patients, using a novel sequential vaccine regimen of BioSante's Pancreas Cancer Vaccine and CRS-207.
CRS-207 is Aduro's lead Lm-based therapeutic and has been engineered to express the tumor-associated antigen, mesothelin. CRS-207 was evaluated in a Phase I trial in 17 end-stage patients with cancers known to express mesothelin: mesothelioma, non-small-cell lung, ovarian and pancreatic. Analysis after the completion of the trial revealed a mesothelin-specific T cell response in multiple patients and despite an expected survival of three-five months for all subjects, six out of 17 subjects lived 15 months or longer.
BioSante cancer vaccines are based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine. BioSante has a portfolio of cancer vaccines, including Pancreas Cancer Vaccine and Prostate Cancer Vaccine. The Pancreas Cancer Vaccine has been evaluated in more than 120 patients and shown to be well tolerated and able to induce mesothelin-specific T cell responses.
Sequential administration of BioSante Pancreas Cancer Vaccine followed by CRS-207 was first shown by Aduro to be synergistic in mouse models, demonstrating enhanced tumor-specific T cell and anti-tumor responses. Because BioSante Pancreas Cancer Vaccine and CRS-207 target the tumor-associated antigen mesothelin, the sequential administration is a heterologous prime-boost regimen. Lm is known to be especially effective in this regimen.
Based on the synergy in preclinical animal models, Drs. Elizabeth Jaffee and Dung Le of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins included three pancreatic cancer patients, in the CRS-207 Phase 1 clinical trial who had previously received the BioSante Pancreas Cancer Vaccine, as part of separate clinical trials. All three late-stage patients who received sequential therapy lived 15 months or longer.
Drs. Jaffee and Le have been instrumental in collaborating with Aduro to design the Phase II trial, which is expected to initiate in the fourth quarter of 2011 and enroll a total of 90 late-stage pancreatic cancer patients. In addition, Dr. Jaffee is one of the original inventors of the BioSante Cancer Vaccines and has many years of experience developing the vaccines.
"The synergy from the sequential administration of BioSante's Pancreas Cancer Vaccine and CRS-207 has the potential to significantly extend and improve the lives of a patient population where progress has historically been measured by extra weeks of survival," said Stephen Isaacs, chairman and chief executive officer of Aduro BioTech. "This partnership may very well represent the future of immunotherapy in which combination therapy becomes the standard."
About Aduro BioTech
Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years and has been validated by 20 major publications and more than $20 million in federal and private grant and contract funding. The company's lead therapeutic, CRS-207, is in clinical development for the treatment of mesothelin-expressing tumors, including pancreatic and non-small-cell lung cancer, and has completed Phase 1.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
Friday, April 15, 2011
Be part of this year's biggest and best online mining investor conference; Follow the Money in Mining and Metals
April 15, 2011 (Investorideas.com Mining stocks newswire) Investorideas.com and SmallCapVoice.com, announce this years online investor mining conference, 'Follow the Money in Mining and Metals'. Current speakers include well-known industry experts, Peter Grandich and Lawrence Roulston. Additional speakers and companies will be added in the coming week. Investorideas.com hosted several online conferences in 2007 and 2008 with over 30 presenting companies. SmallCapVoice.com will be managing the audio and production for this online event, predicted to be the biggest and best online mining investment conference to date.
The conference is free to investors with login registration.
The online event scheduled for May 25th and May26th will feature leading industry experts speaking on the future of the mining sector, along with management of well- followed mining stocks.
The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST.
Learn more about the conference
http://www.smallcapvoice.com/ii_scv/index.html
Free Investor sign-up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Company sign-up
http://www.smallcapvoice.com/ii_scv/company-signup.html
Speakers:
Peter Grandich
Grandich is the founder of Grandich.com and Grandich Publications, LLC, and is editor of The Grandich Letter which was first published in 1984. On his internationally-followed blog, he comments daily about the world’s economies and financial markets and posts his views on social and political topics. He also blogs about a variety of timely subjects of general interest and interweaves his unique brand of humor and every-man “Grandichism” expressions with his experience gained from more than 25 years in and around Wall Street. The result is an insightful and intuitive look at business, finances and the world, set in a vernacular that just about anyone can understand. In his first year, Grandich’s wildly-popular blog had more than one million views. Grandich also provides a variety of services to publicly-held corporations on a compensation basis.
Lawrence Roulston http://www.resourceopportunities.com Roulston, editor, is a geologist, with engineering and business training, and more than 20 years of hands-on experience in the resource industry. Lawrence is ideally suited to publish Resource Opportunities. After completing his studies at the University of British Columbia in 1975, Mr. Roulston worked as an analyst for Cominco Ltd. and for a mid-sized Calgary oil group for several years. In 1984 he became the CFO for a group of mineral exploration companies. He was also vice-president in an investment management firm focused on the resource industry. From 1994 to 1997, he was CEO and director of a mineral exploration company.
More coming soon. If you would like to present, please contact us below.
About InvestorIdeas.com: Investor Ideas that Can Change the World
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source - Investorideas.com, SmallCapVoice.com
April 15, 2011 (Investorideas.com Mining stocks newswire) Investorideas.com and SmallCapVoice.com, announce this years online investor mining conference, 'Follow the Money in Mining and Metals'. Current speakers include well-known industry experts, Peter Grandich and Lawrence Roulston. Additional speakers and companies will be added in the coming week. Investorideas.com hosted several online conferences in 2007 and 2008 with over 30 presenting companies. SmallCapVoice.com will be managing the audio and production for this online event, predicted to be the biggest and best online mining investment conference to date.
The conference is free to investors with login registration.
The online event scheduled for May 25th and May26th will feature leading industry experts speaking on the future of the mining sector, along with management of well- followed mining stocks.
The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST.
Learn more about the conference
http://www.smallcapvoice.com/ii_scv/index.html
Free Investor sign-up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Company sign-up
http://www.smallcapvoice.com/ii_scv/company-signup.html
Speakers:
Peter Grandich
Grandich is the founder of Grandich.com and Grandich Publications, LLC, and is editor of The Grandich Letter which was first published in 1984. On his internationally-followed blog, he comments daily about the world’s economies and financial markets and posts his views on social and political topics. He also blogs about a variety of timely subjects of general interest and interweaves his unique brand of humor and every-man “Grandichism” expressions with his experience gained from more than 25 years in and around Wall Street. The result is an insightful and intuitive look at business, finances and the world, set in a vernacular that just about anyone can understand. In his first year, Grandich’s wildly-popular blog had more than one million views. Grandich also provides a variety of services to publicly-held corporations on a compensation basis.
Lawrence Roulston http://www.resourceopportunities.com Roulston, editor, is a geologist, with engineering and business training, and more than 20 years of hands-on experience in the resource industry. Lawrence is ideally suited to publish Resource Opportunities. After completing his studies at the University of British Columbia in 1975, Mr. Roulston worked as an analyst for Cominco Ltd. and for a mid-sized Calgary oil group for several years. In 1984 he became the CFO for a group of mineral exploration companies. He was also vice-president in an investment management firm focused on the resource industry. From 1994 to 1997, he was CEO and director of a mineral exploration company.
More coming soon. If you would like to present, please contact us below.
About InvestorIdeas.com: Investor Ideas that Can Change the World
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source - Investorideas.com, SmallCapVoice.com
WhisprWave Small Craft Intrusion Barrier and Vessel Exclusion Barrier Products designated as Qualified Anti-Terrorism Technologies
SUMMIT , N.J. - April 15, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. reports the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT). Wave Dispersion Technologies, the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of HomelandSecurity (DHS) SAFETY Act Designation.
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation," said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology," said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
SUMMIT , N.J. - April 15, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. reports the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT). Wave Dispersion Technologies, the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation," said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology," said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Tech Stock News; Investor Ideas adds New Cloud Computing Stock, GBS
Enterprises, Inc. (OTCBB: GBSX) to List of Cloud Stocks
POINT ROBERTS, Wash., April 15 2011 - www.InvestorIdeas.com, a leader
in sector stock research adds cloud computing stock, GBS Enterprises, Inc.
(OTCBB: GBSX) as a featured company on the site and its recently created
directory of cloud computing stocks.
GBS Enterprises, Inc. (OTCBB:GBSX) is the parent company of Group
Business Software (GBS) which provides a portfolio of Cloud Computing
software technologies and Application Services to address the needs of private
enterprises, Data Center providers, ISV's, OEM's as well as government
organizations. GBS caters primarily to mid-market and enterprise B2B size
organizations. GBS has over 3,500 customers in thirty-eight countries spanning
four continents, representing more than 5,000,000 active users of its products.
Recent News:
GBS Enterprises (OTCBB:GBSX) Acquires PAVONE AG, a Leading Provider of Business
Process Management Technologies for the IBM Lotus Platforms
FRANKFURT, Germany - April 14, 2011 (Investorideas.com cloud computing stocks newswire) – GBS
Enterprises, Inc. (OTCBB:GBSX) announced today the acquisition of PAVONE AG, a leader in business
process management and optimization technologies. PAVONE's extensive workflow software for Lotus
Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy.
This acquisition of PAVONE complements GBS's majority ownership in Group Business Software (GBS),
and further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud
computing technology offerings beyond the IBM Lotus market.
Full news : http://www.investorideas.com/CO/GBS/news/2011/04141.asp
Visit the GBSX company profile on Investorideas.com
Visit the Cloud computing stocks directory at Investorideas.com
http://www.investorideas.com/TSS/Cloud_Computing_Stocks.asp
Request news and info on GBSX
Company Contact:
Gary MacDonald
EVP and Chief Corporate Development Officer
GBS Enterprises, Incorporated
+1.917.477.9509
gmacdonald@gbsx.us
Sign up for the free investor news letter and get stock alerts in leading
sectors!
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include;
cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks,
water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no
guarantees as to the accuracy of information presented. All Information relating to featured companies is
sourced from public documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online advertising.
Disclosure: GBS Enterprises, Inc. (OTCBB: GBSX) is a paid showcase tech stock, cloud computing stock on
Investorideas.com (April 2011 - 1500 per month by third party)
www.InvestorIdeas.com/About/Disclaimer.asp
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary
companies. These forward-looking statements are often identified by the use of forward-looking terminology such
as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and
uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed,
estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only
as of the date of this press release. The Company's actual results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors.
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Enterprises, Inc. (OTCBB: GBSX) to List of Cloud Stocks
POINT ROBERTS, Wash., April 15 2011 - www.InvestorIdeas.com, a leader
in sector stock research adds cloud computing stock, GBS Enterprises, Inc.
(OTCBB: GBSX) as a featured company on the site and its recently created
directory of cloud computing stocks.
GBS Enterprises, Inc. (OTCBB:GBSX) is the parent company of Group
Business Software (GBS) which provides a portfolio of Cloud Computing
software technologies and Application Services to address the needs of private
enterprises, Data Center providers, ISV's, OEM's as well as government
organizations. GBS caters primarily to mid-market and enterprise B2B size
organizations. GBS has over 3,500 customers in thirty-eight countries spanning
four continents, representing more than 5,000,000 active users of its products.
Recent News:
GBS Enterprises (OTCBB:GBSX) Acquires PAVONE AG, a Leading Provider of Business
Process Management Technologies for the IBM Lotus Platforms
FRANKFURT, Germany - April 14, 2011 (Investorideas.com cloud computing stocks newswire) – GBS
Enterprises, Inc. (OTCBB:GBSX) announced today the acquisition of PAVONE AG, a leader in business
process management and optimization technologies. PAVONE's extensive workflow software for Lotus
Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy.
This acquisition of PAVONE complements GBS's majority ownership in Group Business Software (GBS),
and further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud
computing technology offerings beyond the IBM Lotus market.
Full news : http://www.investorideas.com/CO/GBS/news/2011/04141.asp
Visit the GBSX company profile on Investorideas.com
Visit the Cloud computing stocks directory at Investorideas.com
http://www.investorideas.com/TSS/Cloud_Computing_Stocks.asp
Request news and info on GBSX
Company Contact:
Gary MacDonald
EVP and Chief Corporate Development Officer
GBS Enterprises, Incorporated
+1.917.477.9509
gmacdonald@gbsx.us
Sign up for the free investor news letter and get stock alerts in leading
sectors!
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include;
cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks,
water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no
guarantees as to the accuracy of information presented. All Information relating to featured companies is
sourced from public documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online advertising.
Disclosure: GBS Enterprises, Inc. (OTCBB: GBSX) is a paid showcase tech stock, cloud computing stock on
Investorideas.com (April 2011 - 1500 per month by third party)
www.InvestorIdeas.com/About/Disclaimer.asp
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary
companies. These forward-looking statements are often identified by the use of forward-looking terminology such
as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and
uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed,
estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only
as of the date of this press release. The Company's actual results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors.
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Investor Ideas announces 1st quarter performance of 32% for its Solar Stocks Portfolio
Point Roberts, South Salem, New York –April 15, 2011 - Investorideas.com, a leader in sector stock
research including renewable energy stocks, reports on 1st quarter performance of 32% for its Solar
Portfolio, created by solar contributor J. Peter Lynch.
Investor Ideas solar portfolio was UP 32% for the first quarter of 2011 vs the general markets increase of
5.3%. This outperformance follows the solar portfolio's full year 2010 performance of +43% verses the
general markets increase of 13%, this is especially impressive in light of the fact that the balance of the
stocks in the solar sector were DOWN an average of 14% in 2010. In addition, the 2010 performance was
accomplished with no turnover (zero trades) made in 2010.
Follow Solar Stocks Commentary with J Peter Lynch
Read his articles and commentary on solar stocks
http://www.investorideas.com/PL/
Read the technical review and portfolio of solar stocks
http://www.investorideas.com/PL/Solar-Stocks-Review.asp
Mr. Lynch has worked, for 33 years as a Wall Street security analyst, an independent security analyst
and private investor in small emerging technology companies. He has been actively involved in following
developments in the renewable energy sector since 1977 and is regarded as an expert in this field. He
was the contributing editor for 17 years to the Photovoltaic Insider Report, an early publication in PV
that was directed at industrial subscribers, such as major energy companies, utilities and governments
around the world. He is currently a private investor and has from time to time been a financial/technology
consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please
visit his website for the promotion of solar energy – www.sunseries.net.
Subscribe to the Peter Lynch solar RSS feed; http://www.investorideas.com/RSS/feeds/PL.xml
Disclaimer: The views and opinions expressed in the research published are those of the individual
companies and writers and not necessarily those of Investorideas.com® or any of the industry sector
portals. At the time of publication, writers may hold positions in the stocks or companies mentioned.
Research other solar with the renewable energy stocks directory; a global stock
directory featuring over 1100 green stocks. Investors also have the option to access the directory
as part of the Investor Ideas Membership premium content that currently features an additional
10 stock directories, including the water stocks directory and all cleantech stock directories. http://
www.investorideas.com/membership/
About InvestorIdeas.com:InvestorIdeas.com is a leader in investor stock research by sector. Sectors
we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks,
energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About Investor Ideas Green Investor content: Visit our showcase green stocks and research green
stocks at: www.renewableenergystocks.com and http://www.investorideas.com/GI/
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies is sourced from public documents and/ or the company
and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and
online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/
Clientspecifics.asp
For more information contact:
Dawn Van Zant 800.665.0411, Email: dvanzant@investorideas.com or Cali at
cvanzant@investorideas.com
Source: www.Investorideas.com
Point Roberts, South Salem, New York –April 15, 2011 - Investorideas.com, a leader in sector stock
research including renewable energy stocks, reports on 1st quarter performance of 32% for its Solar
Portfolio, created by solar contributor J. Peter Lynch.
Investor Ideas solar portfolio was UP 32% for the first quarter of 2011 vs the general markets increase of
5.3%. This outperformance follows the solar portfolio's full year 2010 performance of +43% verses the
general markets increase of 13%, this is especially impressive in light of the fact that the balance of the
stocks in the solar sector were DOWN an average of 14% in 2010. In addition, the 2010 performance was
accomplished with no turnover (zero trades) made in 2010.
Follow Solar Stocks Commentary with J Peter Lynch
Read his articles and commentary on solar stocks
http://www.investorideas.com/PL/
Read the technical review and portfolio of solar stocks
http://www.investorideas.com/PL/Solar-Stocks-Review.asp
Mr. Lynch has worked, for 33 years as a Wall Street security analyst, an independent security analyst
and private investor in small emerging technology companies. He has been actively involved in following
developments in the renewable energy sector since 1977 and is regarded as an expert in this field. He
was the contributing editor for 17 years to the Photovoltaic Insider Report, an early publication in PV
that was directed at industrial subscribers, such as major energy companies, utilities and governments
around the world. He is currently a private investor and has from time to time been a financial/technology
consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please
visit his website for the promotion of solar energy – www.sunseries.net.
Subscribe to the Peter Lynch solar RSS feed; http://www.investorideas.com/RSS/feeds/PL.xml
Disclaimer: The views and opinions expressed in the research published are those of the individual
companies and writers and not necessarily those of Investorideas.com® or any of the industry sector
portals. At the time of publication, writers may hold positions in the stocks or companies mentioned.
Research other solar with the renewable energy stocks directory; a global stock
directory featuring over 1100 green stocks. Investors also have the option to access the directory
as part of the Investor Ideas Membership premium content that currently features an additional
10 stock directories, including the water stocks directory and all cleantech stock directories. http://
www.investorideas.com/membership/
About InvestorIdeas.com:InvestorIdeas.com is a leader in investor stock research by sector. Sectors
we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks,
energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About Investor Ideas Green Investor content: Visit our showcase green stocks and research green
stocks at: www.renewableenergystocks.com and http://www.investorideas.com/GI/
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies is sourced from public documents and/ or the company
and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and
online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/
Clientspecifics.asp
For more information contact:
Dawn Van Zant 800.665.0411, Email: dvanzant@investorideas.com or Cali at
cvanzant@investorideas.com
Source: www.Investorideas.com
Thursday, April 14, 2011
Green Car Stocks Trading Alert; Investors Rush into Green IPO for Zipcar (NASDAQ: ZIP)
Point Roberts, WA - April 14 , 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in sector stock research including the green and renewable energy sector reports on trading for newly listed green rental car company Zipcar (NASDAQ: ZIP). The stock’s IPO debut gains investor interest in the sector again as it trades at $28.25 up 10.25 (56.94%), trading as high as $31.50.
Zipcar sold 6,666,667 shares of common stock and certain selling stockholders are offering 3,017,442 shares of common stock. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,452,617 shares at the initial public offering price.
Zipcar intends to use the net proceeds from this offering for repayment of certain debt, business expansion, working capital and other general corporate purposes, including the development of new services, sales and marketing activities and capital expenditures. Zipcar will not receive any proceeds from the sale of shares by the selling stockholders.
Green Car Company Snapshots
Zipcar (NASDAQ: ZIP). Zipcar is the world's leading car sharing network with more than 560,000 members and over 8,000 vehicles in urban areas and college campuses throughout the United States, Canada and the United Kingdom. Zipcar offers more than 30 makes and models of self-service vehicles by the hour or day to residents and businesses looking for an alternative to the high costs and hassles of owning a car.
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles
Visit the showcase page at Investorideas.com
http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 11 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Research more info on green stocks:
http://www.investorideas.com/gi/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
Point Roberts, WA - April 14 , 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in sector stock research including the green and renewable energy sector reports on trading for newly listed green rental car company Zipcar (NASDAQ: ZIP). The stock’s IPO debut gains investor interest in the sector again as it trades at $28.25 up 10.25 (56.94%), trading as high as $31.50.
Zipcar sold 6,666,667 shares of common stock and certain selling stockholders are offering 3,017,442 shares of common stock. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,452,617 shares at the initial public offering price.Zipcar intends to use the net proceeds from this offering for repayment of certain debt, business expansion, working capital and other general corporate purposes, including the development of new services, sales and marketing activities and capital expenditures. Zipcar will not receive any proceeds from the sale of shares by the selling stockholders.
Green Car Company Snapshots
Zipcar (NASDAQ: ZIP). Zipcar is the world's leading car sharing network with more than 560,000 members and over 8,000 vehicles in urban areas and college campuses throughout the United States, Canada and the United Kingdom. Zipcar offers more than 30 makes and models of self-service vehicles by the hour or day to residents and businesses looking for an alternative to the high costs and hassles of owning a car.
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles
Visit the showcase page at Investorideas.com
http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 11 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Research more info on green stocks:
http://www.investorideas.com/gi/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
'Natural gas stocks and Natural gas companies' most searched by Investors on Investorideas.com as Oil Prices Spiked
Natural Gas Stocks Directory Updated for April
Investorideas.com covers leading sectors for investors with research tools including stock directories, news, articles and featured stocks within each sector.
Sectors covered include oil and gas, natural gas, defense, biotech, mining, nanotech, water, tech, agriculture and other high profile sectors.
Natural gas stocks directory preview:
The complete natural gas stocks directory is part of the Investorideas.com member’s login content of 12 stock directories including oil and gas stocks and renewable energy stocks directory.
3D Oil Limited (ASX.TSO.AX) engages in the production and development of upstream oil and gas properties in Australia. It holds a 100% interest in the Gippsland Basin exploration permit Vic/P57 covering an area of 750 square kilometers located in offshore Victoria; and the Bass Basin exploration permit T41-P covering approximately 2,805 square kilometers located in Tasmania.
Abraxas Petroleum Corporation ( NasdaqCM:AXAS) is a San Antonio based crude oil and natural gas exploration and production company with operations across the Rocky Mountain, Mid-Continent, Permian Basin and onshore Gulf Coast regions of the United States and in the province of Alberta, Canada.
Abu Dhabi National Energy Company PJSC (ADX:TAQA.AE) is a global energy company with operations in power generation, water desalination, upstream oil/gas, pipelines and gas storage. In addition to supplying more than 98% of power in its domestic market, TAQA is expanding its footprint across the Middle East, The Americas and Europe. It is one of the largest companies listed on the ADX.
ACTIVENERGY INCOME TRUST UNITS (AEU-UN.TO) is a TSX listed closed-end investment fund that invests in a diversified portfolio of energy companies with an emphasis on oil and gas as well as common shares of Canadian and U.S.-based issuers operating in the energy sector.
Adams Resources And Energy (AMEX:AE) together with its subsidiaries, engages in marketing crude oil, natural gas, and petroleum products. It purchases crude oil, and arranges sales and deliveries to refiners and other customers in Texas and Louisiana with additional operations in Michigan and New Mexico; purchases, distributes, and markets natural gas; and offers value added services by providing access to common carrier pipelines and handling daily volume balancing requirements, as well as risk management services. The company also markets branded and unbranded refined petroleum products, such as motor fuels comprising automotive gasoline, biodiesel, and conventional diesel fuel; and lubricants consisting of passenger car motor oils, and industrial oils and greases. In addition, it involves in railroad servicing industry by fueling and lubricating locomotives, as well as performing routine maintenance on the power units; and operates as a direct-to-vessel marine fuel and lube vendor primarily in Texas Gulf Coast and southern Louisiana. Further, the company transports liquid chemicals on a ‘for hire’ basis in the continental United States and Canada, as well as engages in the exploration and development of domestic oil and natural gas properties primarily in Texas and the south central region of the United States.
Adelaide Energy Limited (ASX:ADE.AX) is focused on oil and gas exploration in the Cooper and Otway Basins of South Australia. .
Admiral Bay Resources Inc (TSX:ADB.V) is an unconventional gas production company focused on the development of projects in the Cherokee Basin in southeast Kansas and the Appalachian Basin in Pennsylvania.
Advance Energy Limited (ASX.AVD.AX) is focused on the acquisition and development of oil and gas producing assets in Texas USA. The company aims to acquire assets with a combination of debt and equity that have current production and cash flow and to enhance production and cash flow through the further development of these assets. Once a property has reached its full productive potential and/or has achieved economic payout to Advance Energy, the Company looks to on sell all or part of its interest. It is the aim of the Company to develop a portfolio of assets which will be developed and traded to maximise returns on funds invested.
Advantage Energy Income Fund (TSX:AVN-UN.TO; NYSE:AAV) is a conventional oil and gas royalty trust that acquires and develops reserves in Western Canada. The Trust’s head office is located in Calgary, Alberta, Canada. Growth has been achieved through a series of corporate and property acquisitions combined with an active drilling program, which has increased production from 7,300 boe/d at inception in 2001 to approximately 30,000 to 34,000 boe/d in 2009. From inception through December 2008 the Trust’s reserve life index has increased from 7.2 years to 15.2 years.
AGL Resources (NYSE:AGL) an Atlanta-based energy services company, serves approximately 2.3 million customers in six states. The company also owns Houston-based Sequent Energy Management, an asset manager serving natural gas wholesale customers throughout North America. As a 70 percent owner in the SouthStar partnership, AGL Resources markets natural gas to consumers in Georgia under the Georgia Natural Gas brand. The company also owns and operates Jefferson Island Storage & Hub, a high-deliverability natural gas storage facility near the Henry Hub in Louisiana.
Visit the natural gas stocks directory : http://www.investorideas.com/Companies/NaturalGas/Stock_List.asp
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Cloud Computing Stock News; GBS Enterprises (OTCBB:GBSX) Acquires PAVONE AG, a Leading Provider of Business Process Management Technologies for the IBM Lotus Platforms
FRANKFURT, Germany - April 14, 2011 (Investorideas.com cloud computing stocks newswire) � GBS Enterprises, Inc. (OTCBB:GBSX) announced today the acquisition of PAVONE AG, a leader in business process management and optimization technologies. PAVONE's extensive workflow software for Lotus Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy. This acquisition of PAVONE complements GBS's majority ownership in Group Business Software (GBS), and further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud computing technology offerings beyond the IBM Lotus market.
"By joining the family of GBS Enterprise companies allows our customers a broader range of support and technology options in North America and Europe," says Professor Ludwig Nastansky, PhD, Chairman of the Board of PAVONE AG. "This will allow us to increase our R&D investment in areas of cloud computing, mobility, email and CRM management, and analytics."
In his comments Joerg Ott, Chairman and CEO of GBS Enterprises, said that: "PAVONE is a strong and well timed addition to GBS. This acquisition brings us technology, a synergistic customer base and more than 40 employees spanning engineering, sales and services. PAVONE provides GBS with an excellent workflow technology to incorporate into our Lotus offerings, plus PAVONE Live is a workflow engine that can be utilized beyond the Lotus market as a cloud based solution on demand which is ideal for GBS's cloud technology offerings." Joerg also mentioned that "GBS will be able to extend its footprint in banking and insurance and have access to a new supplier vertical. In addition to their great software and extensive customer base, we get great people with the specific skills sets we need to drive the company forward." Ott noted too that GBS Experts, the consulting services group at GBS, will now be able to leverage the workflow engine in any of their custom development engagements.
PAVONE currently has offices in Germany and the UK. They have over 2,500 customers and over 150,000 users worldwide. Some of their customers include Deutsche Bundes Bank, BMW, Linde AG, Philips, British Sugar and Mahle Industries.
About GBS Enterprises, Inc.
GBS Enterprises, Inc. is the parent company of Group Business Software (GBS) which provides a portfolio of Cloud Computing software technologies and Application Services to address the needs of private enterprises, Data Center providers, ISV's, OEM's as well as government organizations. GBS caters primarily to mid-market and enterprise B2B size organizations. GBS has over 3,500 customers in thirty-eight countries spanning four continents, representing more than 5,000,000 active users of its products.
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.
Contact:
Gary MacDonald
EVP and Chief Corporate Development Officer
GBS Enterprises, Incorporated
+1.917.477.9509
gmacdonald@gbsx.us
FRANKFURT, Germany - April 14, 2011 (Investorideas.com cloud computing stocks newswire) � GBS Enterprises, Inc. (OTCBB:GBSX) announced today the acquisition of PAVONE AG, a leader in business process management and optimization technologies. PAVONE's extensive workflow software for Lotus Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy. This acquisition of PAVONE complements GBS's majority ownership in Group Business Software (GBS), and further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud computing technology offerings beyond the IBM Lotus market.
"By joining the family of GBS Enterprise companies allows our customers a broader range of support and technology options in North America and Europe," says Professor Ludwig Nastansky, PhD, Chairman of the Board of PAVONE AG. "This will allow us to increase our R&D investment in areas of cloud computing, mobility, email and CRM management, and analytics."
In his comments Joerg Ott, Chairman and CEO of GBS Enterprises, said that: "PAVONE is a strong and well timed addition to GBS. This acquisition brings us technology, a synergistic customer base and more than 40 employees spanning engineering, sales and services. PAVONE provides GBS with an excellent workflow technology to incorporate into our Lotus offerings, plus PAVONE Live is a workflow engine that can be utilized beyond the Lotus market as a cloud based solution on demand which is ideal for GBS's cloud technology offerings." Joerg also mentioned that "GBS will be able to extend its footprint in banking and insurance and have access to a new supplier vertical. In addition to their great software and extensive customer base, we get great people with the specific skills sets we need to drive the company forward." Ott noted too that GBS Experts, the consulting services group at GBS, will now be able to leverage the workflow engine in any of their custom development engagements.
PAVONE currently has offices in Germany and the UK. They have over 2,500 customers and over 150,000 users worldwide. Some of their customers include Deutsche Bundes Bank, BMW, Linde AG, Philips, British Sugar and Mahle Industries.
About GBS Enterprises, Inc.
GBS Enterprises, Inc. is the parent company of Group Business Software (GBS) which provides a portfolio of Cloud Computing software technologies and Application Services to address the needs of private enterprises, Data Center providers, ISV's, OEM's as well as government organizations. GBS caters primarily to mid-market and enterprise B2B size organizations. GBS has over 3,500 customers in thirty-eight countries spanning four continents, representing more than 5,000,000 active users of its products.
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.
Contact:
Gary MacDonald
EVP and Chief Corporate Development Officer
GBS Enterprises, Incorporated
+1.917.477.9509
gmacdonald@gbsx.us
Disclosure: GBS Enterprises, Inc. (OTCBB:GBSX) is a paid showcase tech stock, cloud computing stock on Investorideas.com (April 2011 - 1500 per month by third party)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Electric Car Stocks Trading Alert; EVCARCO, Inc. (OTCBB: EVCA) Sets Into Motion an Aggressive Dealership Acquisition Plan for 2011
FT. WORTH, TX � April 14, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (Pinksheets:EVCA) is pioneering a new way to meet the demands of 21st century car buyers. In its latest broad approach, EVCA has set into motion a dealership acquisition program aimed at increasing both corporate presence and overall net value of the corporation in respect to sales and inventory.
Scott O'Neal, COO and Co-Founder of EVCARCO, stated, "Our acquisition plan is to evaluate and acquire dealerships and align the Company with major manufacturers that produce vehicles consumers want to drive. We feel the dealerships that are currently on the market today give EVCARCO the opportunity to build value and move forward in the direction of profitability."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. EVCARCO -- Future Driven®
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
FT. WORTH, TX � April 14, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (Pinksheets:EVCA) is pioneering a new way to meet the demands of 21st century car buyers. In its latest broad approach, EVCA has set into motion a dealership acquisition program aimed at increasing both corporate presence and overall net value of the corporation in respect to sales and inventory.
Scott O'Neal, COO and Co-Founder of EVCARCO, stated, "Our acquisition plan is to evaluate and acquire dealerships and align the Company with major manufacturers that produce vehicles consumers want to drive. We feel the dealerships that are currently on the market today give EVCARCO the opportunity to build value and move forward in the direction of profitability."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. EVCARCO -- Future Driven®
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Subscribe to:
Posts (Atom)